ZEUS: Second-generation DES with 30 days DAPT best in bleeding-risk patients

[frothmouth]

“The use of a second-generation zotarolimus-eluting coronary stent rather than a bare metal stent in conjunction with 30 days of dual antiplatelet therapy (DAPT) in patients deemed at high bleeding risk results in lower 1-year rates of major adverse cardiovascular events and stent thrombosis, acco